Physician profile
Robert Kuo
NPI 1801208657
$4,981.40
in general payments reported to CMS, 2019-2025
34 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $144 · 2021: $330 · 2022: $448 · 2023: $1,018 · 2024: $1,050 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $696.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $693.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $573.76 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $347.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $318.53 | 2024-2025 | Apretude |
| Glaxosmithkline, LLC. | $268.92 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $262.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $228.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.77 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Exact Sciences Corporation | $159.05 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $157.60 | 2021-2024 | |
| Astellas Pharma US INC | $148.77 | 2023-2025 | Veozah |
| Mdd US Operations, LLC | $114.10 | 2019 | |
| Abbott Laboratories | $108.40 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $93.16 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.64 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $72.63 | 2020-2021 | |
| Cranial Technologies, INC | $50.25 | 2019-2021 | |
| Dexcom, INC. | $42.94 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $42.87 | 2019-2022 | |
| Dynavax Technologies Corporation | $38.64 | 2023-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $37.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.13 | 2019-2021 | |
| Sanofi Pasteur INC. | $33.01 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $30.91 | 2023-2024 | Livalo, Zoryve |
| Teva Pharmaceuticals USA, INC. | $28.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.44 | 2019 | |
| Inspire Medical Systems, INC. | $20.93 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.40 | 2023 | Quviviq |
| Braemar Manufacturing, LLC | $20.27 | 2019 | |
| Allergan, INC. | $19.30 | 2019 | |
| Gilead Sciences, INC. | $17.08 | 2025 | |
| Sumitomo Pharma America, INC. | $14.55 | 2025 | Gemtesa |
| Eisai INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.